newsfilter
← Latest News
PR Newswire·

Kodiak Sciences to Present at Three Upcoming Investor Conferences

  • Kodiak Sciences CEO Victor Perlroth will present at the Jefferies Global Healthcare Conference on November 16, 2026, in London.
  • The company will present at the UBS Global Biopharma Conference on November 17, 2026, also in London.
  • CEO Victor Perlroth is scheduled to speak at the 9th Annual Evercore Healthcare Conference on December 1, 2026, in Miami.
  • Live webcasts of these presentations will be available via the "Events and Presentations" section of Kodiak's investor relations website, with replays available for a limited time.
  • Kodiak is developing a portfolio of three late-stage clinical programs targeting the $15 billion anti-VEGF market.
  • Zenkuda has a BLA-ready profile for wet age-related macular degeneration, diabetic retinopathy, retinal vein occlusion, diabetic macular edema, wet AMD, 9th Annual Evercore Healthcare Conference on December 1, 2026, in Miami.
  • KSI-101 is a bispecific protein currently in two BLA-facing Phase 3 studies for Macular Edema Secondary to Inflammation.
  • Topline data for the Pivotal Analysis 1 (PEAK) study of KSI-101 is expected in December 2026, while Pivotal Analysis 2 (PEAK+PINNACLE) data is expected in the second quarter of 2027.
Company
Kodiak Sciences Inc.
Keywords
Kodiak Sciences Inc.